Современные представления о пустулёзном псориазе: патогенез, диагностика, лечение

Псориаз – хроническое заболевание кожи, имеющее разнообразные клинические формы. Редкие варианты пустулезного псориаза связаны с доминированием в патогенезе врожденных и аутовоспалительных иммунных реакций, ведущую роль в которых играет цитокин IL-36. Перспективы терапии генерализованного пустулёзного псориаза связаны с использованием ингибиторов активности этого цитокина. Данные по эффективности лечения генерализованного пустулезного псориаза ингибиторами IL-17A ограничены, хотя препараты более доступны для практической деятельности. Продемонстрирована серия клинических случаев успешного использования нетакимаба в терапии генерализованного пустулёзного псориаза.

1. Sarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. North Clin. Istanb. 2016;3:79–82.

2. Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Int. J. Mol. Sci. 2019;20:1475.

3. Круглова Л.С, Бакулев Л. А., Коротаева Т.В, и др., «Псориаз», 2022 г.

4. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin. Dermatol. 2007;25:535–546.

5. Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev. Clin. Immunol. 2019;15:907–919.

6. Bissonnette R, et al. Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway. J. Dermatol. Sci. 2017;85:20–26.

7. Twelves S, et al. Clinical and genetic differences between pustular psoriasis subtypes. J. Allergy Clin. Immunol. 2019;143:1021–1026.

8. Bangale-Daflapurkar S, Danve A. Pustular psoriasis of pregnancy successfully treated with cyclosporine. Am. J. Ther. 2016;23: e1250–e1252.

9. Owczarczyk-Saczonek A, Znajewska-Pander A, Owczarek W, Maciejewska-Radomska A, Placek W. Clinicopathologic retrospective analysis of annular pustular psoriasis. Acta Dermatovenerol. Alp. Pannonica Adriat. 2018;27:215–219.

10. Huang YW, Tsai TF. Juvenile-onset pustular psoriasis: case series and literature review. Br. J. Dermatol. 2020;182:816–817.

11. Sanchez NP, Perry HO, Muller SA, Winkelmann RK. Subcorneal pustular dermatosis and pustular psoriasis. A clinicopathologic correlation. Arch. Dermatol. 1983;119:715–721.

12. Uppala R, Tsoi LC, Harms PW, Wang B, Billi AC, Maverakis E, Michelle Kahlenberg J, Ward NL, Gudjonsson JE. «Autoinflammatory psoriasis»-genetics and biology of pustular psoriasis. Cell Mol Immunol. 2021;18(2):307–317.

13. Круглова Л. С., Моисеев С. В. Блокада интерлейкина-17 – новые горизонты эффективности и безопасности в лечении псориаза. Клиническая фармакология и терапия. 2017;2:5–12.

14. Johnston A, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J. Allergy Clin. Immunol. 2017;140:109–120.

15. Navarini AA, et al. European consensus statement on phenotypes of pustular psoriasis. J. Eur. Acad. Dermatol. Venereol. 2017;31:1792–1799.

16. Onoufriadis A, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am. J. Hum. Genet. 2011;89:432–437.

17. Boutet MA, et al. Distinct expression of interleukin (IL)-36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn’s disease. Clin. Exp. Immunol. 2016;184:159–173.

18. Aksentijevich I, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 2009;360:2426–2437.

19. Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr. Opin. Immunol. 2017;49:1–8.

20. Trivedi MK, Vaughn AR, Murase JE. Pustular psoriasis of pregnancy: current perspectives. Int J. Women’s Health. 2018;10:109–115.

21. Ross MG, Tucker DC, Hayashi RH. Impetigo herpetiformis as a cause of postpartum fever. Obstet. Gynecol. 1984;64:49S-51S.

22. Yamashita T, et al. An effective and promising treatment with adalimumab for impetigo herpetiformis with postpartum flare-up. Int J. Dermatol. 2019;58:350–353.

23. Choon SE, et al. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J. Dermatol. 2014;53:676–684.

24. Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br. J. Dermatol. 1968;80:771–793.

25. Ryan TJ, Baker H. The prognosis of generalized pustular psoriasis. Br. J. Dermatol. 1971;85:407– 411.

26. Zelickson BD, Muller SA. Generalized pustular psoriasis. A review of 63 cases. Arch. Dermatol. 1991;127:1339–1345.

27. Feldmeyer L, Heidemeyer K, Yawalkar N. Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy. Int. J. Mol. Sci. 2016;17:1214.

28. Larsabal M, et al. GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Br. J. Dermatol. 2019;180:647–656.

29. Ozturk G, et al. Generalized pustular eruptions due to terbinafine. Cutan. Ocul. Toxicol. 2012;31:81–84.

30. Gammoudi R, et al. Acute generalized exanthematous pustulosis induced by oxacillin confirmed by patch testing. Contact Dermat. 2018;79:108–110. 31.Webster GF. Pustular drug reactions. Clin. Dermatol. 1993;11:541–543.

31. Абдулганиева Д. И., Бакулев А. Л., Белоусова Е. А., Знаменская Л. Ф., Коротаева Т. В., Круглова Л. С., Кохан М. М., Лила А. М., Хайрутдинов В. Р., Халиф И. Л., Хобейш М. М. Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности, терапевтической эффективности и применению генно-инженерных биологических препаратов у пациентов с сочетанными иммуновоспалительными заболеваниями (псориаз, псориатический артрит, болезнь Крона). Современная ревматология. 2018;3:4–18.

32. Saeki H, et al. Juvenile pustular psoriasis associated with steroid withdrawal syndrome due to topical corticosteroid. J. Dermatol. 2008;35:601–603. 33.Vasconcellos JB, et al. Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis. Bras. Dermatol. 2016;91:137–139.

33. Соколовский Е. В., Круглова Л. С., Понич Е. С. "Болевые" точки системной терапии биологическими препаратами при псориазе. Российский журнал кожных и венерических болезней. 2015; 6:32–38.

34. Jiyad Z, Moriarty B, Creamer D, Higgins E. Generalized pustular psoriasis associated with Epstein-Barr virus. Clin. Exp. Dermatol. 2015; 40: 146–148.

35. Yoneda K, Matsuoka-Shirahige Y, Demitsu T, Kubota Y. Pustular psoriasis precipitated by cytomegalovirus infection. Br. J. Dermatol. 2012; 167: 1186–1189.

36. Pouessel G, et al. Childhood pustular psoriasis associated with Panton-Valentine leukocidin-producing Staphylococcus aureus. Pediatr. Dermatol. 2007; 24: 401–404.

37. Miot HA, Miot LD, Lopes PS, Haddad GR, Marques SA. Association between palmoplantar pustulosis and cigarette smoking in Brazil: a case-control study. J. Eur. Acad. Dermatol. Venereol. 2009; 23: 1173–1177.

38. Wilsmann-Theis, D. et al. Palmoplantar pustulosis – a cross-sectional analysis in Germany. Dermatol. Online J.23 (2017).

39. Bachelez H, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N. Engl. J. Med. 2019; 380: 981–983. doi: 10.1056/NEJMc1811317. [DOI] [PubMed] [Google Scholar]

40. McDermott MF, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR 1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999; 97: 133–144.

41. Brydges S, Kastner DL. The systemic autoinflammatory diseases: inborn errors of the innate immune system. Curr. Top. Microbiol. Immunol. 2006; 305: 127–160.

42. Huffmeier U, Watzold M, Mohr J, Schon MP, Mossner R. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br. J. Dermatol. 2014; 170: 202–204.

43. Henry CM, et al. Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines. Cell Rep. 2016; 14: 708–722.

44. Clancy DM, Henry CM, Sullivan GP, Martin SJ. Neutrophil extracellular traps can serve as platforms for processing and activation of IL-1 family cytokines. FEBS J. 2017; 284: 1712–1725.

45. Vigne S, et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood. 2011; 118: 5813–5823.

46. Mutamba S, Allison A, Mahida Y, Barrow P, Foster N. Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9. Eur. J. Immunol. 2012; 42: 607–617.

47. Arakawa A, et al. Unopposed IL-36 activity promotes clonal CD 4(+) T-cell responses with IL-17A production in generalized pustular psoriasis. J. Invest. Dermatol. 2018; 138: 1338–1347.

48. Benoit S, Toksoy A, Brocker EB, Gillitzer R, Goebeler M. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br. J. Dermatol. 2004; 150: 1009–1012.

49. Imafuku S, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J. Dermatol. 2016; 43: 1011–1017.

50. Young K. Z. Sarkar MK, Gudjonsson JE. Pathophysiology of generalized pustular psoriasis. Exp Dermatol. 2023 Aug;32(8):1194–1203.

51. Robinson A, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J. Am. Acad. Dermatol. 2012; 67: 279–288.

52. Torii H, Nakagawa H, Japanese Infliximab Study Investigators Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J. Dermatol. 2011; 38: 321–334.

53. Kimura U, et al. Generalized pustular psoriasis-like eruptions induced after the first use of adalimumab in the treatment of psoriatic arthritis. J. Dermatol. 2012; 39: 286–287.

54. Wendling D, et al. Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy. Jt. Bone Spine. 2008; 75: 315–318.

55. Arakawa A, Ruzicka T, Prinz JC. Therapeutic efficacy of interleukin 12/interleukin 23 blockade in generalized pustular psoriasis regardless of IL36RN mutation status. JAMA Dermatol. 2016; 152: 825–828.

56. Bissonnette R, et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J. Eur. Acad. Dermatol. Venereol. 2014; 28: 1298–1305.

57. Husson, B. et al. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J. Eur. Acad. Dermatol. Venereol.10.1111/jdv.16265 (2020).

58. Mrowietz U, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J. Am. Acad. Dermatol. 2019; 80:1344–1352.

59. Mansouri B, Richards L, Menter A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1beta inhibitor gevokizumab. Br.J. Dermatol. 2015; 173: 239–241.

60. Skendros P, et al. Successful response in a case of severe pustular psoriasis after interleukin-1beta inhibition. Br. J. Dermatol. 2017; 176: 212–215.

61. Mansouri B, Kivelevitch D, Campa M, Menter A. Palmoplantar pustular psoriasis unresponsive to the interleukin-1beta antagonist canakinumab. Clin. Exp. Dermatol. 2016; 41: 324–326.

62. Инструкция к препарату Эфлейра (нетакимаб), https://www.rlsnet.ru/drugs/efleira-80199